Fluidigm has announced that MLL Munich Leukemia Laboratory (http://www.mll.com/) has used the company's Access Array™ technology to help it uncover mutations in over 80 percent of chronic myelomonocytic leukemia (CMML) patients, providing new insights into the molecular heterogeneity of the disease. MLL researchers applied the unique properties of the Fluidigm Access Array System to prepare the samples and barcode the amplicons for next-generation deep-sequencing using 454 sequencing technology.
In a Letter to the Editor entitled "Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance" published in the February 22, 2011 issue of Nature LEUKEMIA (www.nature.com/leu) magazine, researchers found mutations in 81.5 percent of CMML patients providing new insights into the molecular heterogeneity of leukemia.
In a Letter to the Editor entitled "Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance" published in the February 22, 2011 issue of Nature LEUKEMIA (www.nature.com/leu) magazine, researchers found mutations in 81.5 percent of CMML patients providing new insights into the molecular heterogeneity of leukemia.
No comments:
Post a Comment